Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Inclusion criteria : I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that is refractory to hormone therapy (received prior castration by orchiectomy and/or internal medicine, and documented progression of disease or relapse) who has previously been treated with docetaxel. I 02. Signed informed consent prior to beginning protocol specific procedures. I 03. Patients with PSA \>20 ng/mL at screening. Exclusion criteria: E 01. Age \<20 and \>74 E 02. ECOG performance status ≥2. E 03. Prior surgery ≤4 weeks of registration in the study. E 04. Active secondary cancer including prior malignancy from which the patient has been disease-free for ≤5 years (However, adequately treated superficial basal cell skin cancer before 4 weeks prior to registration can be eligible to the study) E 05. Inadequate organ function including: Neutrophils \<2.0 x 109/L Platelets \<100 x 109/L Hemoglobin \<9.0 g/dL (transfusion prohibition within 14 days before registration) Creatinine \>1.5 mg/dL. Total bilirubin \>1.5 times the upper normal limits of the institutional norms ALT/AST \>1.5 times the upper normal limits of the institutional norms E 06. Previous treatment with \<225 mg/m2 cumulative dose of Taxotere® (or docetaxel). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.